car-nk Archives -

Harnessing the power of natural killer (NK) cells to attack cancer is as-yet an unproven strategy in oncology

New Nkarta data backs up natural killer approach to cancer treatment

https://pharmaphorum.com/news/new-data-backs-up-nkarta-natural-killer-approach-to-cancer/

Shares in Nkarta more than doubled yesterday on the results of early-stage clinical that suggested it could be

Nkarta leaps on early CAR-NK data in blood cancers

https://pharmaphorum.com/news/nkarta-leaps-on-early-car-nk-data-in-blood-cancers/

Gilead Sciences’ cell therapy Kite Pharma has bulked up its position in natural killer (NK) cell therapies, pledging

Gilead combs Shoreline for NK cell therapies in $2.3bn alliance

https://pharmaphorum.com/news/gilead-combs-shoreline-for-nk-cell-therapies-in-2-3bn-alliance/

Catamaran Bio has weighed anchor with a $42 million first-round financing that will be used to pull its

Catamaran joins the CAR-NK fleet, raising $42m in first round

https://pharmaphorum.com/news/catamaran-joins-the-car-nk-fleet-raising-42m-in-first-round/

car-nk